< BACK

 

Hugo Harrod

 

Hugo Harrod is a partner at MVM Partners LLP, which he joined in 2005, and has managed investments from both the London and Boston offices. Hugo currently serves on the boards of SkyCell AG and Nalu Medical, Inc as well as ProVerum. He was previously a director of Gynesonics, Inc (acquired by Hologic), Vertos Medical, Inc (acquired by Stryker), Horizon Discovery Limited (LSE: HZD, acquired by PerkinElmer), Accuvein, Inc, eZono AG and Vantia Limited, and he led MVM’s investment into BioVex Limited (acquired by Amgen). Hugo received financial training at KPMG and holds a degree in Molecular and Cellular Biochemistry from Oxford University.